This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk_2: Thank you for standing by and welcome
spk_1: to profile
spk_2: medical First quarter 2021. Conference call at this time. All participants are and I listen on the note after the speaker's presentation. There will be a question and answer session to ask the question. During the session. You will need to press star one on your telephone. Please be advised at today's conference is being recorded. If you require any further assistance, please first start zero. I would now like to have the conference over to your speaker today, Stephen killer with investor relations.
spk_0: Thank you. Good afternoon everyone. Let me start by pointing out that this conference call will include forward looking statements regarding profound in its business, which may include but is not limited to expectations regarding the efficacy of profound technology in the treatment of prostate cancer. Bph uterine, fibroids, palette of pain and osteo osteopenia. Often, but not always forward looking statements can be identified by the use of words such as plans, it's expected, expects scheduled intense, contemplates, anticipates believes, proposes or variations, including negative variations of such words and phrases, or state that certain actions, events or results may could would might or will be taken occur or be achieved. Such statements are based on the current expectations of management before looking. Events and circumstances discussing. This conference call may not occur by certain specified dates or at all, and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device, industry, economic factors, the equity markets generally and risk associated with growth and competition. Although profound, is attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward looking statements. There may be other factors that cause actions, events of results that differ from most anticipated estimated or intended. No forward looking statement can be guaranteed except as required by applicable securities laws. Forward looking statements speak only as of the date on which they are made. And profound undertakes no obligation to publicly update or revise any forward looking statement whether as a result of new information, future events or otherwise other than is required by law for the benefit of those who are new to the profound story. I would like to take a moment to summarize our business profound develops and markets customizable incision free therapies for the ablation of disease tissue. We are currently commercialized in Tulsa Pro, a technology that combines real time FmRI robotically driven trans urethral ultrasound and closed loop temperature feedback control. The technology is designed to provide customizable and predictable radiation pre ablation of a surgeon to find prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Tulsa pro is ce marked health Canada approved and 5 10 K cleared by the FDA. We are also commercialized info on a leaf and the innovative therapeutic platforms at A. C. Mark for the treatment of uterine fibroids and power the pain treatment of bone metastases. Finally, it has also been approved by the china National Medical Products Administration for the non invasive treatment of uterine fibroids and has recently obtained FDA approval under humanitarian device exemption for the treatment of Osteo Oid osteo. No, well we did not expect this FDA HD approval to have a material impact on revenues in the near term. It is a significant milestone for our company and we are making preparations for its US. commercial launch later in 2021 on the call today representing the company or doctor room and what profound. Chief executive officer and Aaron Davidson, the company's chief financial officer and senior vice president of corporate development. That said I'll turn the call over to Aaron
spk_1: Good afternoon everyone And welcome to our first quarter of 2,021 conference call on behalf of the management team and everyone that profound. I would like to thank you for your ongoing interest in our company. For those of you who are shareholders, we appreciate your continued interest and support. I will turn the call over to a run in a moment for an update on our commercial activities. However, before I do, I'd like to provide a brief update on our first quarter 2021 financial results. A quick reminder that we've changed our presentation currency from the Canadian dollar to the U. S. Dollar to streamline things. All of the numbers we will refer to have been rounded so are approximate. Our first quarter 2000 and 21 sales performance was significantly negatively affected by Covid 19 impacts, particularly in the months of january and february, resulting in our first revenue declines since Key 1, 2000 and 18 For the three month period ended March 31 2020.
Disclaimer